WO2018114469A1 - In vitro cellular co-culture method to induce immunological tolerance - Google Patents
In vitro cellular co-culture method to induce immunological tolerance Download PDFInfo
- Publication number
- WO2018114469A1 WO2018114469A1 PCT/EP2017/082380 EP2017082380W WO2018114469A1 WO 2018114469 A1 WO2018114469 A1 WO 2018114469A1 EP 2017082380 W EP2017082380 W EP 2017082380W WO 2018114469 A1 WO2018114469 A1 WO 2018114469A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- peripheral blood
- lscs
- pbmc
- cell
- Prior art date
Links
- 238000000338 in vitro Methods 0.000 title claims abstract description 12
- 238000003501 co-culture Methods 0.000 title abstract description 16
- 230000001413 cellular effect Effects 0.000 title description 7
- 230000001900 immune effect Effects 0.000 title description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 40
- 210000000130 stem cell Anatomy 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 210000000056 organ Anatomy 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 53
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 16
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 14
- 208000015023 Graves' disease Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 239000012091 fetal bovine serum Substances 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- 229960005322 streptomycin Drugs 0.000 claims description 8
- 208000023328 Basedow disease Diseases 0.000 claims description 7
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- 239000006143 cell culture medium Substances 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 239000012997 ficoll-paque Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 230000006058 immune tolerance Effects 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- -1 sodium bicarbonate pyridoxine Chemical compound 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 229930182816 L-glutamine Natural products 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 3
- 230000005660 hydrophilic surface Effects 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 206010043778 thyroiditis Diseases 0.000 claims description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 7
- 208000027754 Endocrine autoimmune disease Diseases 0.000 claims 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 abstract description 21
- 210000004698 lymphocyte Anatomy 0.000 abstract description 17
- 239000000427 antigen Substances 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 3
- 230000003614 tolerogenic effect Effects 0.000 abstract description 3
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 32
- 208000001204 Hashimoto Disease Diseases 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 26
- 108090000695 Cytokines Proteins 0.000 description 26
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 22
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 16
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 15
- 229940100601 interleukin-6 Drugs 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 230000004913 activation Effects 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 11
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000001506 immunosuppresive effect Effects 0.000 description 11
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 10
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 238000000506 liquid--solid chromatography Methods 0.000 description 10
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 9
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 9
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 9
- 102100026019 Interleukin-6 Human genes 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 8
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 8
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 8
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 8
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 8
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 8
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 101100395318 Homo sapiens HLA-G gene Proteins 0.000 description 6
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 108050003558 Interleukin-17 Proteins 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000002124 endocrine Effects 0.000 description 6
- 210000004700 fetal blood Anatomy 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000016736 Cyclin Human genes 0.000 description 5
- 108050006400 Cyclin Proteins 0.000 description 5
- 108010039471 Fas Ligand Protein Proteins 0.000 description 5
- 108010024164 HLA-G Antigens Proteins 0.000 description 5
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 208000003532 hypothyroidism Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101150000157 ARHGEF1 gene Proteins 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 230000003832 immune regulation Effects 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 101150055452 lsc gene Proteins 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 2
- 101000658124 Apomastus schlingeri Mu-cyrtautoxin-As1a Proteins 0.000 description 2
- 102100036465 Autoimmune regulator Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 101710091439 Major capsid protein 1 Proteins 0.000 description 2
- 101100001794 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aps-2 gene Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000002017 Autoimmune Hypophysitis Diseases 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101710088098 Forkhead box protein P3 Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 description 1
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 description 1
- 101100434583 Mus musculus Aire gene Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 238000011531 Quantitect SYBR Green PCR kit Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101710150974 Regulator of chromosome condensation Proteins 0.000 description 1
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009743 cell cycle entry Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000021095 non-nutrients Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 208000011610 primary hypophysitis Diseases 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002707 regulatory b cell Anatomy 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1388—Mesenchymal stem cells from other natural sources
Definitions
- the present invention refers to the biotechnology field, since it provides an in vitro method to induce immuno-tolerance of peripheral blood mononuclear cells (PBMCs) from patients with auto-immune organ- specific diseases by co-culture with human autologous and/or heterologous limbal mesenchymal stem cells (f-LSCs) .
- PBMCs peripheral blood mononuclear cells
- f-LSCs human autologous and/or heterologous limbal mesenchymal stem cells
- the PBMCs are "educated” to recognize self antigens and can be used for the treatment of autoimmune-specific diseases such us chronic Hashimoto thyroiditis (HT) , Addison's disease, hypoparathyroidism, autoimmune hypophysics, Graves disease, Type 1 diabetes, vitiligo, etc. and autoimmune poly-endocrine syndromes (APS) , wherein the single clinical manifestations combine with each other (APS-1, APS-2, APS-3) .
- HT Hashi
- thyroiditis refers to intra-thyroid lymphocyte infiltration with or without thyroid dysfunction.
- autoimmune thyroiditis includes a wide spectrum of diseases (Autoimmune thyroid disease AITD) such as idiopathic mixedema, Hashimoto thyroiditis (HT) and Graves' disease (GD) , with different clinical manifestations linked to immunological reactivity against thyroid autoantigens.
- AITD Autoimmune thyroid disease
- HT Hashimoto thyroiditis
- GD Graves' disease
- Intra-thyroid lymphocytes have a central role in the pathogenesis of autoimmune thyroid diseases due to the recognition of thyroid autoantigens in the follicular cells of the gland that stimulates T and B lymphocyte, activation triggering a vicious circle.
- lymphocytes mediate significant pro- and antiinflammatory effects imputable to the release of different cytokines (IFN- ⁇ , TNF- , TNF- ⁇ , IL2, IL6, IL8, IL10) .
- T helper (Th) sub-types have improved our understanding of the function of immune system. It is known that differentiation into the Thl or Th2 phenotype is closely dependent on the cytokine environment generated [Kidd P. Thl/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003; 8:223- 246] .
- Hashimoto's thyroiditis or chronic lymphocytic thyroiditis the gland is affected by a variety of cell- and antibody-mediated immune processes. This condition is the most common cause of hypothyroidism in the world and it is about seven times more frequent in women than in men. To date, thyroid hormone replacement or conventional and unspecific immunosuppressive regimens cannot provide a cure for HT subjects, who will have a poor quality of life, as in other chronic autoimmune diseases.
- MSCs Mesenchymal Stem Cells
- BM bone marrow
- CB-MSCs Cord Blood-MSCs
- P-MSCs Placenta-MSCs
- A-MSCs Adipose-MSCs
- CBSCs cord blood-derived multipotent stem cells
- MSCs act deeply on the immune response through their interaction with the different cellular components of the innate (natural killer, NK) and adaptive immune system (dendritic cells, B and T lymphocytes) .
- Immune regulation is induced both by direct cellular contact and by the release of various factors (TGF- ⁇ , PD-L1 /2 , HLAG, IDO, IL-6, HGF, COX-2, MCP-1 (CCL2) ) .
- the cornea consists of three major layers, which are derived from different germ layers: the epithelial layer develops from the ectoderm, whereas the stroma and endothelium are mesenchymal in origin.
- the majority of the corneal thickness consists in the stromal layer, whereas the endothelial monolayer sits on Descemet's membrane, which is the most posterior part of the cornea.
- the absence of blood and lymphatic vessels is assumed to give a condition termed "corneal immune privilege" [Azar DT .
- Corneal angiogenic privilege Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis , and wound healing (an American Ophthalmological Society thesis. Trans Am Ophthalmol Soc 2006; 104:264 -302] .
- the limbus is a highly specialized region of the eye hosting a well- recognized population of epithelial stem cells (LESCs), which continuously renew the corneal surface [Davanger, M. ; Evensen, A. Role of the pericorneal papil- lary structure in renewal of corneal epithelium. Nature. 1971. 229 (5286) : 560-1] and stromal invaginations rich in stromal fibroblast-like stem cells (f-LSCs), with multilineage transdifferentiation potential [Dravida, S . ; Pal, R. ; Khanna, A.; Tipnis, S. P.; Ravindran, G.; Khan, F.
- Interferon gamma is a proinflammatory cytokine that can induce expression of HLA class II (HLA-DR) molecules in many cell types including BM-MSCs .
- HLA-DR HLA class II
- f-LSCs act as "smart immunomodulators" improving their phenotype and their expression for immunoregulatory mediators, such as Programmed death-ligand 1 and 2 (PDL-1/2), Interleukin 6 (IL-6) and Monocyte chemoattractant protein-1 (MCP-1), after exposure to several Thl cytokines (IL-6, IL- ⁇ ; IFN- ⁇ ) and, at the same time, maintaining expression for HLA-DR and co-stimulatory molecules negative.
- PDL-1/2 Programmed death-ligand 1 and 2
- IL-6 Interleukin 6
- MCP-1 Monocyte chemoattractant protein-1
- PBMCs peripheral blood mononuclear cells
- human f-LSCs are a precious and easy source of mesenchymal stem cells to be used in all therapeutic strategies that require immunosuppression and attenuation of inflammatory status in a variety of autoimmune diseases including HT .
- the present invention aims to provide an in vitro method for reeducation of auto-reactive lympho-monocytes from subjects with autoimmune organ-specific diseases and/or associated autoimmune endocrine diseases .
- Stem Cell Education works as an in vitro "artificial thymus" able to induce tolerance of treated lympho-monocytes, reestablishing the immunological balance and homeostasis.
- an exiguous number of f-LSCs are co-cultivated with lympho-monocytes in a 1:100 ratio.
- a new in vitro strategy for treating Hashimoto's disease with immunomodulated autologous lymphocytes is proposed as an alternative therapy to the conventional corticosteroids, anti-inflammatory drugs, immunosuppressors and hormonal replacement regimens, eliminating the ethical concerns associated with other therapeutic approaches based on the use of stem cells.
- PBMCs auto-reactive peripheral blood mononuclear cells
- f-LSCs limbal stem cells
- An other object of the present invention is the self-immuno-educated mononuclear cells of peripheral blood (PBMCs) obtained by the aforementioned method.
- PBMCs peripheral blood
- Another object of the present invention is the use of self-educated peripheral blood mononuclear cells (PBMCs) obtained by the aforementioned method for the treatment of auto-immune organ-specific diseases and/or autoimmune endocrine associated diseases.
- PBMCs peripheral blood mononuclear cells
- Figure 1 shows the immunological profile of f-LSCs assessed by flow cytometry before (left panel) and after 48 hours of cytokine-treatment (IL- ⁇ , IL-6 and IFNy, 500 U/ml) (right panel) for: the human leukocyte antigens (HLA-DR) , the immune T-activator molecule programmed death-1 (PD-1, CD279) and its ligands (Programmed death- ligand 1/2, PDL-1/2), the negative regulator of T cell response B7-H4 and the co-stimulatory molecules CD80 and CD86.
- HLA-DR human leukocyte antigens
- PD-1 immune T-activator molecule programmed death-1
- PDL-1/2 the immune T-activator molecule programmed death-1
- the negative regulator of T cell response B7-H4 the co-stimulatory molecules CD80 and CD86.
- Cytokine treatment in f-LSCs increases the expression for PD-L1 and PD-L2 and weakly for B7H4 (40 ⁇ 2.3% vs 7013.5, 66 ⁇ 4.2% vs 8612.5 e 411.5 vs 10.212 respectively) . All histogram plots include the percentage of expression as a representative value of five independent experiments.
- Figure 2 shows the qRT-PCR of several immunosuppressive and tolerogenic markers (HLA-G, TGF- ⁇ , IDO, COX-2, HGF, PDL-l/2Fas, Fas-L, MCP-, IL-6 and AIRE) in f-LSCs before and after cytokine stimulation.
- HLA-G immunosuppressive and tolerogenic markers
- IDO immunosuppressive and tolerogenic markers
- COX-2 HGF
- PDL-l/2Fas Fas-L
- MCP- MCP-
- IL-6 and AIRE IL-6 and AIRE
- FIG. 3 shows the proliferation assay (MTT) of F-LSCs plated with or without cytokine up to 72 hours. During cytokine stimulation f-LSCs appeared to grow moderately faster than untreated ones. The graph is representative of at least five independent experiments.
- Figure 4 shows the DNA content assessed using Propidium Iodide/Etidium Bromide staining and analysed by flow cytometry.
- PBMCs from healthy volunteers were stimulated with anti-CD3/28 for 72 hours in the presence or absence of f-LSCs. Analysis of the cell cycle showed that 85.011.2% of activated PBMCs were blocked in the G0/G1 phase when cocultured with f-LSCs .
- FACS plots are representative of 5 experiments of identical design.
- Figure 5 shows the marked down-regulation of the two activation markers CD28 and PD-1 in PBMCs collected from young volunteers after 72h of coculture. Higher levels of CD69 (21% ⁇ 1.9 vs. 39% ⁇ 2.1) were detected under the same conditions in activated PBMCs co-cultured with f-LSCs. Samples were run after 72 hours of incubation with or without f-LSCs . All data are representative of at least five independent experiments. Values on the bars are shown as mean ⁇ SE, *p ⁇ 0.05, **p ⁇ 0.02.
- Figure 6 shows the inversion of the CD4/CD8 ratio in activated PBMCs from healthy volunteers after co-culture for 72h with f-LSCs compared to untreated activated PBMCs . Each figure shows an experiment representative of five replicates. Data are presented as means ⁇ SE in each histogram. **p ⁇ 0.02.
- Figure 7 shows a weak reduction in the percentage of CD4 + CD25 hl9h in activated PBMCs from healthy controls co-cultivated for 72h with f- LSCs compared to untreated activated PBMCs. Notably, inside the gated CD4 + CD25 hl9h population no differences in percentage of CD4 + Foxp3 + cells were detected when f-LSCs were added to the culture. Each figure shows an experiment representative of five replicates. Data are presented as means ⁇ SE in each histogram. *p ⁇ 0.05.
- Figure 8 shows the PBMC proliferation status, assessed by the CFSE method, after seven days of coculture. Unactivated PBMCs labelled with CFSE were used as a negative control. Cytofluorometric analyses revealed, in activated PBMCs from volunteers, the reduction of the proliferation index from 3.8410.3 to 2.5 ⁇ 0.5 after co-culture with f- LSCs (100:1 ratio) and from 1.7510.1 to 2.2710.5 in PBMCs of patients with HT under the same conditions. Each figure shows an experiment representative of five replicates. Data are presented as means ⁇ SE in each histogram. *p ⁇ 0.05.
- Figure 9 shows the down-modulation of inflammatory cytokines such as IFN- ⁇ , IL-17A, and the transcription factor for IL-17A, ROR- ⁇ induced by f-LSCs in activated PBMCs of HT patients after 72h of co-culture.
- IL-4s like Th2 cytokines, appear to be induced in co- cultivated lymphocytes, compared to controls. Data derive from one of five independent experiments.
- peripheral blood mononuclear cells are T and B lymphocytes, NK (natural killer) cells and monocytes.
- Peripheral blood mononuclear cells are human cells obtained from patients with autoimmune organ-specific diseases and/or with autoimmune endocrine associated disorders.
- self-reactive cells are cells with auto-antigen responsiveness and able to induce cyto- destruction of the target tissue and/or immuno-flogosis .
- the induction of immunological tolerance is the re-education of auto-reactive cells to recognize self antigens.
- self-educated cells are cells that are tolerant towards autologous tissue peripheral antigens.
- f-LSCs are referred to fibroblastic-like stem cells derived from the stromal niche of the limbus .
- Limbal stem cells are heterologous because they do not express HLA class II antigens even if exposed to inflammatory cytokines .
- cell culture media are media suitable for cell growth in vitro, which usually regards the presence of a saline physiological buffer where low molecular weight nutrients are dissolved, such as sugars, aminoacids, vitamins and non- nutrients such as ions, swabs and dyes.
- a saline physiological buffer where low molecular weight nutrients are dissolved, such as sugars, aminoacids, vitamins and non- nutrients such as ions, swabs and dyes.
- hydrophilic surface culture flasks are any plastic containers suitably treated to make the surfaces in contact with the cells hydrophilic and capable of enhancing cellular adhesion and expansion.
- auto-immune organ- specific diseases are disorders in which the autoimmune response is directed against multiple antigens of the same organ. Typically, they involve endocrine glands and the autoantibodies often are represented by specific hormone receptors or intracellular enzymes of the affected tissue, as in chronic Hashimoto's thyroiditis (HT) , Addison's disease, hypoparathyroidism, autoimmune hypophysitis, Graves disease, type 1 diabetes, vitiligo, etc.
- HT Hashimoto's thyroiditis
- Addison's disease hypoparathyroidism
- autoimmune hypophysitis autoimmune hypophysitis
- Graves disease type 1 diabetes, vitiligo, etc.
- associated autoimmune endocrine diseases are disorders where different clinical manifestations are associated with each other to characterize different forms (APS-1, APS-2, APS-3) .
- the present invention refers to an in vitro method for re-establishing immune tolerance in auto-reactive peripheral blood mononuclear cells (PBMCs) by co-culture with limbal stem cells (f-LSCs) in a 100:1 ratio .
- PBMCs peripheral blood mononuclear cells
- f-LSCs limbal stem cells
- the peripheral blood mononuclear cells are obtained from subjects with auto-immune organ-specific diseases and/or endocrine autoimmune associated diseases.
- the limbal stem cells are autologous.
- the limbal stem cells are heterologous as they do not express HLA class II antigens even if exposed to inflammatory cytokines.
- the co-culture is assessed in a cell culture medium without glutamine, HEPES and red phenol, supplemented with glutamine in a concentration of 2-4 mM, and fetal bovin serum FBS in a concentration of 10-12%.
- the culture medium is selected from RPMI-1640 Medium, RPMI-1640 Medium Dutch Modification, RPMI-1640 Medium HEPES Modification, RPMI-1640 Medium Modified and RPMI-1640 Medium Auto-Mod for Autoclaving.
- the culture medium more preferably is RPMI1640 Medium Modified.
- the culture medium can be supplemented with antibiotics.
- the antibiotics are streptomycin and penicillin.
- the antibiotics are present in a concentration between 1000-50000U/ml of penicillin and 50-500mg/ml of streptomycin, and more preferably lOOOOU/ml of penicillin and lOOmg/ml of streptomycin.
- the co-culture is carried out in flasks with treated surfaces for tissue cultures for enhancing the surface charge of the culture containers .
- culture flasks with hydrophilic surface.
- the culture flasks are of polystyrene functionalized with oxygen-containing groups .
- the culture flasks are commercial and pre-treated products to improve cell adhesion.
- culture flasks are Corning®CellBind® .
- the method comprises a step wherein limbal biopsies are plated to grow until adherent colonies of f-LSCs are obtained and expanded in culture medium containing Hepes, sodium bicarbonate and pyridoxine, L-glutamine and supplemented with 5% of bovine fetal serum, IX of insulin-transferrin-selenium and fibroblast growth factor.
- culture medium of the f-LSCs is F12/DMEM.
- the method comprises before co-culture a step wherein PBMCs are obtained from samples of peripheral blood samples by density gradient centrifugation from samples of blood from subjects with autoimmune organ-specific diseases.
- centrifugation is in Ficoll-Paque density gradient.
- Another object of the present invention is self-educated peripheral blood mononuclear cells (PBMCs) obtained by co-culture with limbal stem cells in a 100:1 ratio with the aforementioned method.
- PBMCs peripheral blood mononuclear cells
- Another object of the present invention is the use of self-educated peripheral blood mononuclear cells (PBMCs) obtained by the abovementioned method for the treatment of auto-immune organ-specific diseases .
- PBMCs peripheral blood mononuclear cells
- autoimmune organ-specific diseases are autoimmune endocrine-related disorders.
- autoimmune endocrine-related diseases are autoimmune thyroid diseases (Autoimmune thyroid disease AITD) .
- AITD Autoimmune thyroid disease
- HT Hashimoto's thyroiditis
- GD Graves' disease
- a further subject of the present invention is a kit of parts comprising, in separate containers, all the components necessary to perform the method of the present invention.
- the kit of parts includes peripheral blood mononuclear cells (PBMCs) from organ-specific and/or endocrine autoimmune patients, heterologous and/or autologous limbal stem cells (fLSCs) and all the components necessary to perform the co-culture method of the present invention.
- PBMCs peripheral blood mononuclear cells
- fLSCs heterologous and/or autologous limbal stem cells
- the preferred embodiment of the present invention provides that the PBMCs collected by Ficoll-Paque density gradient of Hashimoto thyroid patients are co-cultivated in RPMI-1640 supplemented with penicillin, streptomycin, L-glutamine and 10% of heat-inactivated bovine fetal serum, with f-LSCs in a 100:1 ratio for 4 hours.
- Two to three mm 2 limbal biotic samples were obtained from 10 patients undergoing surgery for ocular diseases not involving the conjunctiva or corneal surface. Patients gave written informed consent and the IRB of the University of Palermo approved the study in accordance with the Declaration of Helsinki. After 24-48h, adherent colonies of f-LSCs and small cuboidal cells (epithelial) were obtained. At the same time, floating spherical cells or "limbospheres" started forming. The Limbospheres progressively increased in number and size and attached to the plastic surface, eventually generating highly proliferating fibroblast-like outgrowths. To better select f-LSCs from epithelial cells, forming limbospheres were transferred into new flasks.
- Limbal cells were cultured in F12/DMEM medium supplemented with 10% embryonic stem cell-tested fetal bovine serum (FBS; PAA) , IX insulin- transferrinselenium (ITS; PAA) , and 4 ng/ml basic fibroblast growth factor ( FGF; SigmaAldrich) (expansion medium) . Cultures were maintained in 5% CO 2 in a humidified incubator at 37 °C.
- FBS embryonic stem cell-tested fetal bovine serum
- ITS IX insulin- transferrinselenium
- FGF basic fibroblast growth factor
- TPOAb TPOAb and/or Tg antibodies
- TgAb TPOAb and/or Tg antibodies
- All patients were receiving L-T4 replacement therapy in a standard dosage from 75 to 150 meg/die. None of the patients was receiving corticoid or other antiinflammatory therapy. Only one of them was also affected by Turner Syndrome.
- the healthy control group had 10 subjects, of which 8 males and 2 females aged 24-34 years.
- heparin anticoagulated blood Fifteen milliliters of heparin anticoagulated blood was drawn from each donor/patient in the morning after a 12-hour fasting period. The blood was diluted 1:1 with PBS' s solution, and PBMCs were separated by gradient centrifugation over Ficoll.
- PBMCs obtained by Ficoll-Paque density gradient from HT patients were cultured in RPMI-1640 supplemented with penicillin, streptomycin, L- glutamine and 10% heat-inactivated fetal bovine serum.
- L-FSCs were allowed to adhere to 24-well plates overnight and the day after co- cultured with PBMCs at a 1:100 ratio for 4 hours.
- the low f-LSC density in the flasks avoids their detachment while PBMCs were gently recovered as a surnatant.
- the cell cycle of activated PBMCs or cocultured with f-LSCs for 72h was performed according to Nicoletti's protocol and analyzed by flow cytometry (FACSCalibur, Becton Dickinson) . Briefly, cell suspensions were fixed in 70% ethanol and stained with propidium iodide overnight before analysis. f-LSCs were cultured in chamber slides (BD Biosciences) for 48h with or without cytokine and afterwards stained with 1 ⁇ of AO/EB solution (5 mg/ml and 3 mg/ml) . After staining all samples were immediately evaluated under fluorescence microscopy using a fluorescein filter in a 40X lens.
- T-cell phenotype was determined by using CD25 (IL-2 Receptor ) PerCPCyTM5.5, FoxP3 (Scurfin, IPEX, JM2) PE, CD4 FITC, CD69 PE (Very Early Activation Antigen) , CD8 FITC/PE, CD3 FITC, CD152 (CTLA-4) PE, CD28 (TLR2) PE, IFN- ⁇ PE, IL-4 PE, IL-17 PE, RORyt PE, IL-10 PE all purchased from BD Pharmingen.
- Intracellular staining was performed using BD Cytofix/CytopermTM Plus Fixation/Permeabilization Kit (with BD GolgiStopTM proteintransport inhibitor) (BD Pharmingen) , according to the manufacturer's instructions.
- BD GolgiStop protein transport inhibitor containing raonensin, was added in the culture for 5 hours before cellular harvesting.
- f-LSC immunophenotype was determined using the following monoclonal antibodies: HLA-DR FITC, CD80 (B7-1) PE, CD86 (B70/B7-2) PE, PD-1 (CD279) PE, CD34 FITC, CD45 FITC, CD274 (B7-H1, PD-L1) PE, CD273 (B7-DC, PD-L2) PE, B7-H4 PE (BD Biosciences) .
- Freshly isolated PBMCs and a primary Bone Marrow MSCs (Lonza) were used as positive controls for hematopoietic markers and stem cell/immunosuppressive markers respectively. All data were acquired on a FACSCalibur and analyzed using CELLQuest Pro software (Becton Dickinson) and are representative of at least five independent experiments .
- HGF reverse primer 5 TCC TTG ACC TTG GAT GCA TTC 3'
- the primer set for HLA-G was selected to amplify all alternative forms of HLA-G transcripts.
- PCR primers for IL-6, FAS, IDO, MCP1, CCND1 and p27 were purchased from Qiagen (QuantiTect Primer Assays, Qiagen) . All reactions were performed with Quantitect Sybr Green PCR Kit (Qiagen) using the Rotor-Gene Q instrument (Qiagen) . The specificity of the amplified products was determined by melting peak analysis. Relative gene expression analysis for each gene was performed by Rotor-Gene Q software using the delta delta Ct method validated according to the guidelines of Livak and Schmittgen (2001) . Briefly, each sample was first normalized for the amount of template added by comparison with the normalizing gene ( ⁇ -actin) . These normalized values were further normalized relative to a calibrator treatment (untreated control) . All reactions were performed at least in triplicate.
- PBMCs from HT patients and healthy donors were labelled with CellTraceTM Carboxyfluorescein succinimidyl ester (CFSE) using Cell Proliferation Kit (Molecular Probes Invitrogen) , according to the manufacturer's instructions.
- Labeled PBMCs were resuspended in RPMI 1640 medium (Gibco) with 10% FBS (complete 1640 medium) , activated with 5 g/mL of anti CD3/CD28 mAbs (Sigma Aldrich) and cocultured with one-day plated f-LSCs at 100:1 ratio. After 7 days of coculture, PBMCs were gently harvested from the supernatant and CFSE fluorescence detected by flow cytometry. Samples were analyzed by Modfit LT Version 3.2 software (Verity Software House) and the proliferation index calculated as the sum of cells in all generations divided by the number of original parent cells.
- the F-LSCs used in the co-culture experiments exhibited the expected fibroblast-like morphology after Acridine/Orange staining and expressed the phenotypic markers shown in Figure 1.
- Freshly isolated PBMCs and primary Bone Marrow MSCs (Lonza) were used as positive controls for hematopoietic and stem cell/immunosuppressive markers respectively.
- QRT-PCR and flow cytometry staining was performed to determine the presence of key factors involved in immunoregulation .
- f-LSCs constitutively and at the same levels as Bone Marrow-derived MSCs (BMMSCs ) , expressed transcripts required to modulate an immune response like TGF- ⁇ , PDL-1, Aire and Fas.
- BMMSCs Bone Marrow-derived MSCs
- the weak expression of CD95 but the total absence of CD95L in f-LSCs did not suggest Fas-FasL mediated immunoregulation .
- constitutive HLAG, IDO and IL-6 expression were approximately 4/5-fold lower compared to the positive control.
- the primer set used in this study detected for all HLAG mRNA-spliced isoforms.
- f-LSCs significantly differed from BM-MSCs for expression of HGF, COX-2 and the monocyte chemotactic protein-1 (MCP-1 or CCL2 ) found 10, 50, 90- fold higher respectively.
- MCP-1 or CCL2 monocyte chemotactic protein-1
- f-LSCs significantly differed from BM-MSCs for expression of HGF, COX-2 and the monocyte chemotactic protein-1 (MCP-1 or CCL2 ) found 10, 50, 90- fold higher respectively.
- CD274 PD-L1
- CD273 CD273
- Fig 1 and 2 The inhibitory molecules PD-L1 and PDL-2 have been shown to negatively interfere with the immune responses.
- the receptor of these ligands, PD-1 is an immunoinhibitory receptor expressed by activated T cells. Engagement of PD-1 by PD-L1 and PDL-2 leads to inhibition of T-cell receptor-mediated lymphocyte activation.
- f-LSCs exhibited the machinery required
- IL-6 at 250U/ml miming a typical inflammatory environment provided by lymphocytes in patients with HT .
- Fig. ID MTT assay
- Fig. 3 MTT assay
- mRNA for PDL-1, MCP-1 and IL-6 was found upregulated 2, 25 and 60-fold respectively.
- Fig. 1 Taken together these data confirmed the capability of f-LSCs to enhance their immunosuppressive phenotype increasing the key immunomodulator markers PDL-1, PDL-2, IL-6 and MCP1 in an inflammatory environment (Fig. 2) .
- F-LSCs from healthy traditionsies were cocultured with anti-CD3/28 stimulated PBMCs from at 1:100 ratio for 72h.
- PBMCs peripheral blood mononuclear cells
- phase-contrast microscopy we observed that activated lymphocytes formed numbers of cell clumps of different size in the absence of f-LSCs.
- the number of cell clumps was significantly reduced after f-LSC coculture and the majority of lymphocytes were individually distributed in the medium or closely adherent to the f-LSCs. Comparable results were also obtained in mixed leukocyte reactions .
- PBMCs with or without f-LSCs exhibited constitutive levels of cyclin Dl and a high expression level of the negative cell cycle regulatory protein p27Kipl.
- cyclin Dl did not change in expression whereas p27Kipl was significantly downregulated to induce cell cycle entry.
- the expression of p27Kipl was induced in stimulated PBMCs that had been cocultured with f-LSCs, suggesting the possibility that f-LSCs exert their growth inhibitory effect primarily through induction of p27Kipl expression.
- f-LSCs were cocultured 72h with PBMCs from healthy volunteers in the presence of anti-CD3/28 mAbs and analyzed by flow cytometry for some conventional activation markers (CD28, PD-1, CD69) and for CD4 and CD8 T-surface markers.
- CD28, PD-1, CD69 some conventional activation markers
- CD4 and CD8 T-surface markers CD4 and CD8 T-surface markers.
- f-LSCs we found a consistent down- regulation of the two activation markers CD28 and PD-1 in PBMCs collected from young volunteers (66% ⁇ 1.3 vs. 38% ⁇ 3.2 and 17% ⁇ 1.0 vs. 5% ⁇ 1.6 respectively) .
- Higher levels of CD69 (21% ⁇ 1.9 vs. 39% ⁇ 2.1) were detected under the same conditions (Fig. 5) .
- the activation marker CD69 is a target of canonical nuclear factor kappa-B (NF-kB) signaling and is transiently expressed upon activation; however, stable CD69 expression defines cells with immunoregulatory properties.
- NF-kB canonical nuclear factor kappa-B
- late and sustained CD69 expression is promoted by the non-canonical pathway and is inhibited by canonical NF-kB signaling
- Treg cells which are CD4 + CD25 high Foxp3 +
- Treg cells which are CD4 + CD25 high Foxp3 +
- CFSE CFSE we compared the proliferation state of responding PBMCs from healthy controls and HT patients stimulated with anti-CD3 and anti-CD28 mAbs with or without f-LSCs for 72h. Unstimulated PBMCs without f-LSCs were used as a negative control.
- the proliferation index useful for determining the antiproliferative effects of f-LSCs on activated lymphocytes, was calculated as the sum of cells in all generations divided by the number of original parent cells.
- PBMCs from healthy volunteers and HT patients, grown in culture without mitogen antibodies, after a 7 day-period of incubation yielded proliferation indexes of 1.4410.03 and 1.4310.1 respectively (negative control) .
- Stimulation with anti-CD3/28 mAbs significantly increased the proliferation of lymphocytes (proliferation index, 2.510.5 in healthy controls vs. 3.8410.3 in patients) .
- the coculture of anti-CD3/28 stimulated PBMCs with f-LSCs (100:1 ratio) produced a proliferation index of 1.75 ⁇ 0.1 in volunteers vs. 2.2710.5 in HT patients, representing a significant impairment, slightly superior in lymphocytes from patients respect controls, of activated PBMCs .
- MSCs modulate the differentiation, function, and balance of the thl,th2,thl7 subpopulations and foster the development of an anti-inflammatory immune response
- Th balance induced by f-LSCs in activated-PBMCs some typical pro- and anti-inflammatory cytokines and the transcription factors for IL-17A, ROR- ⁇ , were investigated by intracellular flow staining.
- IFN- ⁇ , IL-17A and ROR- ⁇ were considerably decreased in cocultured cells from HT patients compared to only activated cells without f-LSCs (18% ⁇ 2.1 vs. 9% ⁇ 0.9; 69% ⁇ 6.5 vs. 3813.4; 27% ⁇ 1.5 vs. 14% ⁇ 0.6 respectively) .
- f-LSCs did not inhibit, at the same levels, the expression of the aforementioned cytokines on PBMCs from healthy controls (9% ⁇ 1.0 vs. 4% ⁇ 0.9; 8% ⁇ 1.2 vs. 710.4; 20% ⁇ 1.5 vs. 15% ⁇ 1.6 respectively) .
- IL-4 secretion by Th2 was induced in the presence of f-LSCs specially in lymphocytes from HT patients (15% ⁇ 2.1 vs. 28% ⁇ 0.9) compared to healthy donors (20% ⁇ 0.6 vs. 25% ⁇ 0.5) (Fig. 9) .
- f-LSCs specially in lymphocytes from HT patients (15% ⁇ 2.1 vs. 28% ⁇ 0.9) compared to healthy donors (20% ⁇ 0.6 vs. 25% ⁇ 0.5)
- f-LSCs inhibit lymphocyte proliferation and modulate cytokine production. They are also immunologically privileged as they do not express the complete pattern of molecules required to fully activate T-lymphocytes . In particular they are negative for the major histocompatibility (MHC) class II, co-stimulatory (CD80 or CD86) molecules, the hematopoietic markers CD34, CD45 and the epithelial marker ⁇ 63 even if an inflammatory background is present. Their immunomodulatory effects also depend on both cell contact and soluble factors produced. Among them we detected the following: TGF- ⁇ , PDL- 1/2, HLAG, IDO, IL-6, HGF, COX-2 and MCP-1 (CCL2) .
- Human f-LSCs differ from Bone Marrow-derived MSCs for the more elevated expression of HGF, COX-2 and MCP-1. As a consequence of their sensitivity to an inflammatory environment, human f-LSCs adjust their phenotype and their expression for immunoregulatory mediators after exposure to IL- 1 ⁇ and IL-6.
- Our results after 48h of cytokine treatment show the following: maintenance at baseline of mRNA for HLA-G, TGF- ⁇ , IDO and AIRE; preservation at sustained levels of mRNA for COX-2 and HGF; upregulation of mRNA for MCP-1 and IL-6; absence and halving of mRNA for CD95L and CD95 respectively; an increase in PDL-1 and PDL-2 expression at protein level.
- the CD4/CD8 ratio is significantly inverted in PBMCs from healthy donors after coculture with f-LSCs proving a negative regulation action of f-LSCs on CD8+ T cells.
- the CD69 expression is significantly upregulated on activated PBMCs when coculture with f-LSCs becoming immunomodulatory cells.
- Flow cytometry analyses indicate a faint reduction in CD25 expression and preservation of CD4 + FoxP3 + cells in the presence or absence of f-LSCs, suggesting that the suppressive effect of f-LSCs is not mediated through induction of regulatory T cells. Therefore f-LSCs seem to influence the Th subset balance by altering the cytokine profile of T lymphocytes.
- IL- 17A and RORyT human f-LSCs attenuate the differentiation of naive CD4 + T cells into Thl and Thl7 effectors.
- the IL-4 expression is improved by shifting the total balance from Thl-driven responses to a more anti-inflammatory Th2 profile.
- Down-regulation of ROR- ⁇ , the key transcription factor of IL-17A, at protein level suggests the capability of f-LSCs to also modulate Thl7 differentiation in favour of IL-4- producing Th2 cells. This phenomenon is more evident in PBMCs coculture with f-LSCs isolated from HT patients. This effect may depend on an inflammatory background able to stimulate or maintain the immune process in AITD patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An in vitro method able to modulate peripheral blood mononuclear cells of patients with auto-immune organ-specific diseases is described. The protocol makes auto-reactive lymphocytes tolerogenic through a process of re-education in recognition of self-antigen after co-culture with heterologous and/or autologous fibroblast limbal stem cells.
Description
In vitro Cellular co-culture method to induce immunological tolerance
Background of the Invention
The present invention, refers to the biotechnology field, since it provides an in vitro method to induce immuno-tolerance of peripheral blood mononuclear cells (PBMCs) from patients with auto-immune organ- specific diseases by co-culture with human autologous and/or heterologous limbal mesenchymal stem cells (f-LSCs) . The PBMCs are "educated" to recognize self antigens and can be used for the treatment of autoimmune-specific diseases such us chronic Hashimoto thyroiditis (HT) , Addison's disease, hypoparathyroidism, autoimmune hypophysics, Graves disease, Type 1 diabetes, vitiligo, etc. and autoimmune poly-endocrine syndromes (APS) , wherein the single clinical manifestations combine with each other (APS-1, APS-2, APS-3) .
State of the art
The current meaning of "thyroiditis" refers to intra-thyroid lymphocyte infiltration with or without thyroid dysfunction.
According to this definition, "autoimmune thyroiditis" includes a wide spectrum of diseases (Autoimmune thyroid disease AITD) such as idiopathic mixedema, Hashimoto thyroiditis (HT) and Graves' disease (GD) , with different clinical manifestations linked to immunological reactivity against thyroid autoantigens. Intra-thyroid lymphocytes have a central role in the pathogenesis of autoimmune thyroid diseases due to the recognition of thyroid autoantigens in the follicular cells of the gland that stimulates T and B lymphocyte, activation triggering a vicious circle.
In this context, lymphocytes mediate significant pro- and antiinflammatory effects imputable to the release of different cytokines (IFN-γ, TNF- , TNF-β, IL2, IL6, IL8, IL10) . Today, identification of the T helper (Th) sub-types has improved our understanding of the
function of immune system. It is known that differentiation into the Thl or Th2 phenotype is closely dependent on the cytokine environment generated [Kidd P. Thl/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003; 8:223- 246] .
In Hashimoto's thyroiditis or chronic lymphocytic thyroiditis the gland is affected by a variety of cell- and antibody-mediated immune processes. This condition is the most common cause of hypothyroidism in the world and it is about seven times more frequent in women than in men. To date, thyroid hormone replacement or conventional and unspecific immunosuppressive regimens cannot provide a cure for HT subjects, who will have a poor quality of life, as in other chronic autoimmune diseases.
Great attention has been paid to other molecular mechanisms which could play a role in the AITD manifestation. Among these, we can remember the most accredited one, that is the FAS/FAS-Ligand system, which is able to trigger the apoptotic pathway in non-physiological conditions. In GD the apoptosis of infiltrating lymphocytes prevails, with limitation to their self-reactive potential, while the thyrocytes are stimulated to survive. By contrast, different regulation of the same apoptotic control system in HT promotes apoptosis of thyrosocytes andtissue damage and leads to hypothyroidism [Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Science 1997 Feb 14; 275 (5302) : 960-3] .
Unfortunately, although the aetiological-pathogenetic origin of AITD has been largely defined and it is possible to identify the risk of developing thyroid diseases based on the well-known natural history (preclinical phase characterized by positivity for antithyreoperoxidase, antithyroglobulin and anti-TSH receptor antibodies), to date there is still no therapy that can stop the
evolution of the clinical manifestations, like overt hyper- or hypothyroidism [Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls. Dan Med J. 2016 Feb; 63 (2) . pii: B517 ; Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM. Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study. Eur J Endocrinol. 2011 Jan; 164 ( 1 ) : 107-13 ] .
Recently it has been proposed that Mesenchymal Stem Cells (MSCs) can contribute to the control of inflammatory diseases, as has been demonstrated by MSC-mediated attenuation of inflammation in myocarditis [Manley, N. R. , Thymus organogenesis and molecular mechanisms of thymic epithelial cell differentiation. Semin. Immunol. 2000. 12: 421-428.], rheumatoid arthritis [Rodewald, H. R., Paul, S., Haller, C., Bluthmann, H. and Blum, C., Thymus medullaconsisting of epithelial islets each derived from a single progenitor. Nature 2001. 414:763-768], and experimental autoimmune diseases [Spits H. Development of alphabeta T cells in the human thymus. Nat Rev Immunol 2002;2:760-72; Von Boehmer H, Fehling HJ. Structure and function of the pre-T cell receptor. Annu Rev Immunol 1997;15:433-52]. Nowadays, due to their regenerative and immunosuppressive properties, MSCs, derived from different adult tissue, have become a preferred cell type in the field of regenerative medicine and immunotherapy.
Although bone marrow (BM) is considered a universal source of multipotent MSCs, displaying the greatest suppressive effects on T cell proliferation, the invasive procedure necessary to harvest these cells, the risks of complications and the age-dependent decline of their self-renewal capacity have led to a search for alternate sources of MSCs. Cord Blood-MSCs (CB-MSCs), Placenta-MSCs (P-MSCs) and Adipose-MSCs (A-MSCs) have been suggested as alternative sources of MSCs for experimental and clinical purposes since they are free from ethical concerns, easy to procure and available in large quantities [Bieback K, kern S, Kluter H, Eichler H. Critical parameters
for the isolation of mesenchymal stem cells from umbilical cord blood. Stem cells 2004 ; 22 ( 4 ) : 625-34 ] . Despite this, only BM- and A-MSCs have the tri-lineage differentiation potential meeting the minimal criteria defined by the International Society for Cellular Therapy. Furthermore BM-, CB- and A-MSCs exhibit replicative senescence when they reach passage 10 on average, whereas P-MSCs expand until passage 15 [Heo JS1, Choi Yl, Kim HS2, Kim HOI . Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016 Jan; 37 (1) : 115- 25] .
An attempt at "Stem Cell Educator Therapy" induced by CB-MSCs has already been described, but only in Type 1/2 Diabetes [Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T. Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med 2012 Jan 10;10:3; Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H, Yin Z, Chen Y, Zhang Y, Wang S, Shen J, Thaker H, Jain S, Li Y, Diao Y, Chen Y, Sun X, Fisk MB, Li H. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CBSCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med. 2013 Jul 9; 11: 160; 10] and Alopecia Areata [Li Y, Yan B, Wang H, Li H, Li Q, Zhao D, Chen Y, Zhang Y, Li W, Zhang J, Wang S, Shen J, Li Y, Guindi E, Zhao Y. Hair regrowth in alopecia areata patients following Stem Cell Educator therapy. BMC MED. 2015 Apr 20;13:87]. Limitations to the use of CB-MSCs include insufficient quantity and quality of MSCs obtainable from a single unit of CB, the potential for transfer of genetically abnormal or pre-malignant cells in patients, and the lack of a National Cord Blood Policy able to manage daily operations of cord blood acquiring, isolation, and cryopreservation . Today only few public cord banks are extracting mesenchymal stem cells from cordon tissue before their cryogenic storage and subsequent nationwide allocation.
MSCs act deeply on the immune response through their interaction with the different cellular components of the innate (natural killer, NK) and adaptive immune system (dendritic cells, B and T lymphocytes) . Immune regulation is induced both by direct cellular contact and by the release of various factors (TGF-β, PD-L1 /2 , HLAG, IDO, IL-6, HGF, COX-2, MCP-1 (CCL2) ) . [Meisel, A. Zibert, M. Laryea, U. G'Obel, W. D"aubener, and D. Dilloo, "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3- dioxygenasemediated tryptophan degradation," Blood, vol. 103, no. 12, pp. 4619-4621, 2004; M. Krampera, L. Cosmi, R. Angeli et al . , "Role for interferon in the immunomodulatory activity of human bone marrow mesenchymal stem cells," Stem Cells, vol. 24, no. 2, pp.386-398, 2006.] .
Nowadays more attention is focusing on the limbus in regenerative medicine. This area of the eye is placed in the junction of the cornea and conjunctiva, where stem cells of mesemchymal origin are placed. The cornea consists of three major layers, which are derived from different germ layers: the epithelial layer develops from the ectoderm, whereas the stroma and endothelium are mesenchymal in origin. The majority of the corneal thickness consists in the stromal layer, whereas the endothelial monolayer sits on Descemet's membrane, which is the most posterior part of the cornea. The absence of blood and lymphatic vessels is assumed to give a condition termed "corneal immune privilege" [Azar DT . Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis , and wound healing (an American Ophthalmological Society thesis. Trans Am Ophthalmol Soc 2006; 104:264 -302] .
The limbus is a highly specialized region of the eye hosting a well- recognized population of epithelial stem cells (LESCs), which continuously renew the corneal surface [Davanger, M. ; Evensen, A. Role of the pericorneal papil- lary structure in renewal of corneal epithelium. Nature. 1971. 229 (5286) : 560-1] and stromal invaginations rich in stromal fibroblast-like stem cells (f-LSCs), with multilineage
transdifferentiation potential [Dravida, S . ; Pal, R. ; Khanna, A.; Tipnis, S. P.; Ravindran, G.; Khan, F. The transdifferentiation potential of limbal fibroblast-like cells. Dev. Brain Res. 160:239- 251; 2005] . All these cellular components are localized in a highly specialized region of the eye called "limbal niche" which provides anatomical and functional dimensions to maintain "sternness," protect stem cells from traumatic and environmental insults, allow epithelial- mesenchymal interactions and supply access to chemical signals that diffuse from the rich underlying vascular network. LESCs have been widely characterized and investigated for their differentiation potential, which seems to be restricted to the corneal destiny. [Chen, Z . ; de Paiva, C. S . ; Luo, L.; Kretzer, F. L . ; Pflugfelder S. C; Li, D. Q. Characterization of putative stem cell phenotype in human limbal epithelia. Stem Cells 22:355-366; 2004]. We recently demonstrated that f-LSCs represent a robust source of adult stem cells with multi- lineage potential, good proliferative capability and long-term maintenance of stem cell properties independently of donor age and long-term culture conditions [Italian Patent Application no. FI2009A000275 ; Criscimanna A, Zito G, Taddeo A, Richiusa P, Pitrone M, Morreale D, Lodato G, Pizzolanti G, Citarrella R, Galluzzo A, Giordano C. In vitro generation of pancreatic endocrine cells from human adult fibroblast-like limbal stem cells. Cell Transplant. 2012; 21 (1) : 73-90; Tomasello L, Musso R, Cillino G, Pitrone M, Pizzolanti G, Coppola A, Arancio W, Di Cara G, Pucci-Minafra I, Cillino S, Giordano C. Donor age and long-term culture do not negatively influence the stem potential of limbal fibroblast-like stem cells. Stem Cell Res Ther. 2016 Jun 13; 7 (1) : 83] .
Interferon gamma (IFN-γ) is a proinflammatory cytokine that can induce expression of HLA class II (HLA-DR) molecules in many cell types including BM-MSCs . By contrast, f-LSCs act as "smart immunomodulators" improving their phenotype and their expression for immunoregulatory mediators, such as Programmed death-ligand 1 and 2 (PDL-1/2), Interleukin 6 (IL-6) and Monocyte chemoattractant protein-1 (MCP-1),
after exposure to several Thl cytokines (IL-6, IL-Ιβ; IFN-γ) and, at the same time, maintaining expression for HLA-DR and co-stimulatory molecules negative. Therefore, unlike other kinds of MSCs, they do not modify their immunoprivileged condition even if an inflammatory background exists. Their immunosuppressive potential, indeed, is expected to be superior in peripheral blood mononuclear cells (PBMCs) from HT patients due to the Thl-driven pathogenesis of thyroiditis compared to healthy controls.
Technical Problem
The authors' research shows that human f-LSCs are a precious and easy source of mesenchymal stem cells to be used in all therapeutic strategies that require immunosuppression and attenuation of inflammatory status in a variety of autoimmune diseases including HT .
The present invention aims to provide an in vitro method for reeducation of auto-reactive lympho-monocytes from subjects with autoimmune organ-specific diseases and/or associated autoimmune endocrine diseases .
Stem Cell Educator Therapy works as an in vitro "artificial thymus" able to induce tolerance of treated lympho-monocytes, reestablishing the immunological balance and homeostasis.
In the method of the present invention, an exiguous number of f-LSCs are co-cultivated with lympho-monocytes in a 1:100 ratio. Thus, a new in vitro strategy for treating Hashimoto's disease with immunomodulated autologous lymphocytes is proposed as an alternative therapy to the conventional corticosteroids, anti-inflammatory drugs, immunosuppressors and hormonal replacement regimens, eliminating the ethical concerns associated with other therapeutic approaches based on the use of stem cells.
Subject matter of the invention
With reference to the attached claims, the technical problem is solved
by providing: an in vitro method to re-establish immune-tolerance in auto-reactive peripheral blood mononuclear cells (PBMCs) by co-culture with limbal stem cells (f-LSCs) in a 100:1 ratio.
An other object of the present invention is the self-immuno-educated mononuclear cells of peripheral blood (PBMCs) obtained by the aforementioned method.
Another object of the present invention is the use of self-educated peripheral blood mononuclear cells (PBMCs) obtained by the aforementioned method for the treatment of auto-immune organ-specific diseases and/or autoimmune endocrine associated diseases.
Brief description of the figures
Figure 1 shows the immunological profile of f-LSCs assessed by flow cytometry before (left panel) and after 48 hours of cytokine-treatment (IL-Ιβ, IL-6 and IFNy, 500 U/ml) (right panel) for: the human leukocyte antigens (HLA-DR) , the immune T-activator molecule programmed death-1 (PD-1, CD279) and its ligands (Programmed death- ligand 1/2, PDL-1/2), the negative regulator of T cell response B7-H4 and the co-stimulatory molecules CD80 and CD86. Cytokine treatment in f-LSCs increases the expression for PD-L1 and PD-L2 and weakly for B7H4 (40±2.3% vs 7013.5, 66±4.2% vs 8612.5 e 411.5 vs 10.212 respectively) . All histogram plots include the percentage of expression as a representative value of five independent experiments.
Figure 2 shows the qRT-PCR of several immunosuppressive and tolerogenic markers (HLA-G, TGF-β, IDO, COX-2, HGF, PDL-l/2Fas, Fas-L, MCP-, IL-6 and AIRE) in f-LSCs before and after cytokine stimulation. Notably, mRNA for IDO and PDL-1 was found to be upregulated 2-fold compared to untreated controls while the mRNA for IL-6 and MCP-1 increased 25 and 60-fold respectively. All data/pictures are representative of at least five independent experiments. Values on the
bars are shown as mean ± SE, *p<0.05, **p<0.02.
Figure 3 shows the proliferation assay (MTT) of F-LSCs plated with or without cytokine up to 72 hours. During cytokine stimulation f-LSCs appeared to grow moderately faster than untreated ones. The graph is representative of at least five independent experiments.
Figure 4 shows the DNA content assessed using Propidium Iodide/Etidium Bromide staining and analysed by flow cytometry. PBMCs from healthy volunteers were stimulated with anti-CD3/28 for 72 hours in the presence or absence of f-LSCs. Analysis of the cell cycle showed that 85.011.2% of activated PBMCs were blocked in the G0/G1 phase when cocultured with f-LSCs . FACS plots are representative of 5 experiments of identical design.
Figure 5 shows the marked down-regulation of the two activation markers CD28 and PD-1 in PBMCs collected from young volunteers after 72h of coculture. Higher levels of CD69 (21%±1.9 vs. 39%±2.1) were detected under the same conditions in activated PBMCs co-cultured with f-LSCs. Samples were run after 72 hours of incubation with or without f-LSCs . All data are representative of at least five independent experiments. Values on the bars are shown as mean ± SE, *p<0.05, **p<0.02.
Figure 6 shows the inversion of the CD4/CD8 ratio in activated PBMCs from healthy volunteers after co-culture for 72h with f-LSCs compared to untreated activated PBMCs . Each figure shows an experiment representative of five replicates. Data are presented as means ± SE in each histogram. **p<0.02.
Figure 7 shows a weak reduction in the percentage of CD4+CD25hl9h in activated PBMCs from healthy controls co-cultivated for 72h with f- LSCs compared to untreated activated PBMCs. Notably, inside the gated CD4+CD25hl9h population no differences in percentage of CD4+Foxp3+ cells were detected when f-LSCs were added to the culture. Each figure shows an experiment representative of five replicates. Data are presented as
means ± SE in each histogram. *p<0.05.
Figure 8 shows the PBMC proliferation status, assessed by the CFSE method, after seven days of coculture. Unactivated PBMCs labelled with CFSE were used as a negative control. Cytofluorometric analyses revealed, in activated PBMCs from volunteers, the reduction of the proliferation index from 3.8410.3 to 2.5 ±0.5 after co-culture with f- LSCs (100:1 ratio) and from 1.7510.1 to 2.2710.5 in PBMCs of patients with HT under the same conditions. Each figure shows an experiment representative of five replicates. Data are presented as means ± SE in each histogram. *p<0.05.
Figure 9 shows the down-modulation of inflammatory cytokines such as IFN-γ, IL-17A, and the transcription factor for IL-17A, ROR-γΤ induced by f-LSCs in activated PBMCs of HT patients after 72h of co-culture. By contrast IL-4s, like Th2 cytokines, appear to be induced in co- cultivated lymphocytes, compared to controls. Data derive from one of five independent experiments.
Detailed description of the invention
Definitions
Within the meaning of the present invention, the peripheral blood mononuclear cells (PBMCs-peripheral blood mononuclear cells) are T and B lymphocytes, NK (natural killer) cells and monocytes. Peripheral blood mononuclear cells (PBMCs) are human cells obtained from patients with autoimmune organ-specific diseases and/or with autoimmune endocrine associated disorders.
Within the meaning of the present invention, self-reactive cells are cells with auto-antigen responsiveness and able to induce cyto- destruction of the target tissue and/or immuno-flogosis .
Within the meaning of the present invention, the induction of immunological tolerance is the re-education of auto-reactive cells to recognize self antigens.
Within the meaning of the present invention, self-educated cells are cells that are tolerant towards autologous tissue peripheral antigens.
Within the meaning of the present invention, f-LSCs are referred to fibroblastic-like stem cells derived from the stromal niche of the limbus .
Limbal stem cells (f-LSCs) are heterologous because they do not express HLA class II antigens even if exposed to inflammatory cytokines .
Within the meaning of the present invention, cell culture media are media suitable for cell growth in vitro, which usually regards the presence of a saline physiological buffer where low molecular weight nutrients are dissolved, such as sugars, aminoacids, vitamins and non- nutrients such as ions, swabs and dyes.
Within the meaning of the present invention, hydrophilic surface culture flasks are any plastic containers suitably treated to make the surfaces in contact with the cells hydrophilic and capable of enhancing cellular adhesion and expansion.
Within the meaning of the present invention, auto-immune organ- specific diseases are disorders in which the autoimmune response is directed against multiple antigens of the same organ. Typically, they involve endocrine glands and the autoantibodies often are represented by specific hormone receptors or intracellular enzymes of the affected tissue, as in chronic Hashimoto's thyroiditis (HT) , Addison's disease, hypoparathyroidism, autoimmune hypophysitis, Graves disease, type 1 diabetes, vitiligo, etc.
Within the meaning of the present invention, associated autoimmune endocrine diseases are disorders where different clinical manifestations are associated with each other to characterize different forms (APS-1, APS-2, APS-3) .
The present invention refers to an in vitro method for re-establishing
immune tolerance in auto-reactive peripheral blood mononuclear cells (PBMCs) by co-culture with limbal stem cells (f-LSCs) in a 100:1 ratio .
Preferably, the peripheral blood mononuclear cells (PBMCs) are obtained from subjects with auto-immune organ-specific diseases and/or endocrine autoimmune associated diseases.
Preferably, the limbal stem cells (f-LSCs) are autologous.
Even more preferably, the limbal stem cells (f-LSCs) are heterologous as they do not express HLA class II antigens even if exposed to inflammatory cytokines.
Preferably, the co-culture is assessed in a cell culture medium without glutamine, HEPES and red phenol, supplemented with glutamine in a concentration of 2-4 mM, and fetal bovin serum FBS in a concentration of 10-12%.
More preferably, the culture medium is selected from RPMI-1640 Medium, RPMI-1640 Medium Dutch Modification, RPMI-1640 Medium HEPES Modification, RPMI-1640 Medium Modified and RPMI-1640 Medium Auto-Mod for Autoclaving.
The culture medium more preferably is RPMI1640 Medium Modified.
Optionally, the culture medium can be supplemented with antibiotics.
Preferably, the antibiotics are streptomycin and penicillin.
Preferably, the antibiotics are present in a concentration between 1000-50000U/ml of penicillin and 50-500mg/ml of streptomycin, and more preferably lOOOOU/ml of penicillin and lOOmg/ml of streptomycin.
Preferably, the co-culture is carried out in flasks with treated surfaces for tissue cultures for enhancing the surface charge of the culture containers .
Preferably, they are culture flasks with hydrophilic surface.
Preferably the culture flasks are of polystyrene functionalized with oxygen-containing groups .
More preferably, the culture flasks are commercial and pre-treated products to improve cell adhesion.
More preferably the culture flasks are Corning®CellBind® .
Optionally, before co-culture the method comprises a step wherein limbal biopsies are plated to grow until adherent colonies of f-LSCs are obtained and expanded in culture medium containing Hepes, sodium bicarbonate and pyridoxine, L-glutamine and supplemented with 5% of bovine fetal serum, IX of insulin-transferrin-selenium and fibroblast growth factor. Preferably the culture medium of the f-LSCs is F12/DMEM.
Optionally, the method comprises before co-culture a step wherein PBMCs are obtained from samples of peripheral blood samples by density gradient centrifugation from samples of blood from subjects with autoimmune organ-specific diseases.
Preferably centrifugation is in Ficoll-Paque density gradient.
Another object of the present invention is self-educated peripheral blood mononuclear cells (PBMCs) obtained by co-culture with limbal stem cells in a 100:1 ratio with the aforementioned method.
Another object of the present invention is the use of self-educated peripheral blood mononuclear cells (PBMCs) obtained by the abovementioned method for the treatment of auto-immune organ-specific diseases .
Preferably, autoimmune organ-specific diseases are autoimmune endocrine-related disorders.
Preferably, autoimmune endocrine-related diseases are autoimmune
thyroid diseases (Autoimmune thyroid disease AITD) .
Preferably, among the AITDs, Hashimoto's thyroiditis (HT) and Graves' disease (GD) are selected.
A further subject of the present invention is a kit of parts comprising, in separate containers, all the components necessary to perform the method of the present invention.
Preferably, the kit of parts includes peripheral blood mononuclear cells (PBMCs) from organ-specific and/or endocrine autoimmune patients, heterologous and/or autologous limbal stem cells (fLSCs) and all the components necessary to perform the co-culture method of the present invention.
The preferred embodiment of the present invention provides that the PBMCs collected by Ficoll-Paque density gradient of Hashimoto thyroid patients are co-cultivated in RPMI-1640 supplemented with penicillin, streptomycin, L-glutamine and 10% of heat-inactivated bovine fetal serum, with f-LSCs in a 100:1 ratio for 4 hours.
Examples
Two to three mm2 limbal biotic samples were obtained from 10 patients undergoing surgery for ocular diseases not involving the conjunctiva or corneal surface. Patients gave written informed consent and the IRB of the University of Palermo approved the study in accordance with the Declaration of Helsinki. After 24-48h, adherent colonies of f-LSCs and small cuboidal cells (epithelial) were obtained. At the same time, floating spherical cells or "limbospheres" started forming. The Limbospheres progressively increased in number and size and attached to the plastic surface, eventually generating highly proliferating fibroblast-like outgrowths. To better select f-LSCs from epithelial cells, forming limbospheres were transferred into new flasks.
Limbal cells were cultured in F12/DMEM medium supplemented with 10% embryonic stem cell-tested fetal bovine serum (FBS; PAA) , IX insulin-
transferrinselenium (ITS; PAA) , and 4 ng/ml basic fibroblast growth factor ( FGF; SigmaAldrich) (expansion medium) . Cultures were maintained in 5% CO2 in a humidified incubator at 37 °C.
Patients with autoimmune thyroiditis and elevated plasma TPOAb and/or Tg antibodies (TgAb) were selected from Policlinico P. Giaccone- University of Palermo and asked for their informed consent to participate in the study. Diagnoses had been made by elevated TPOAb, TgAb, basal TSH levels and colour Doppler ultrasound examination. All patients were receiving L-T4 replacement therapy in a standard dosage from 75 to 150 meg/die. None of the patients was receiving corticoid or other antiinflammatory therapy. Only one of them was also affected by Turner Syndrome. HD patients with other chronic diseases, e.g. diabetes, hypertension, coronary heart, or viral hepatitis, were excluded from this study. The healthy control group had 10 subjects, of which 8 males and 2 females aged 24-34 years. Fifteen milliliters of heparin anticoagulated blood was drawn from each donor/patient in the morning after a 12-hour fasting period. The blood was diluted 1:1 with PBS' s solution, and PBMCs were separated by gradient centrifugation over Ficoll.
PBMCs obtained by Ficoll-Paque density gradient from HT patients were cultured in RPMI-1640 supplemented with penicillin, streptomycin, L- glutamine and 10% heat-inactivated fetal bovine serum. L-FSCs were allowed to adhere to 24-well plates overnight and the day after co- cultured with PBMCs at a 1:100 ratio for 4 hours. The low f-LSC density in the flasks avoids their detachment while PBMCs were gently recovered as a surnatant.
The cell cycle of activated PBMCs or cocultured with f-LSCs for 72h was performed according to Nicoletti's protocol and analyzed by flow cytometry (FACSCalibur, Becton Dickinson) . Briefly, cell suspensions were fixed in 70% ethanol and stained with propidium iodide overnight
before analysis. f-LSCs were cultured in chamber slides (BD Biosciences) for 48h with or without cytokine and afterwards stained with 1 μΐ of AO/EB solution (5 mg/ml and 3 mg/ml) . After staining all samples were immediately evaluated under fluorescence microscopy using a fluorescein filter in a 40X lens. Acridine orange, as a vital dye, stained both live and dead cells while Ethidium bromide only stained cells that had lost membrane integrity. Live cells appeared uniformly green. Early apoptotic cells stained green and contained bright green dots in the nuclei as a consequence of chromatin condensation and nuclear fragmentation. Late apoptotic cells also incorporated ethidium bromide and therefore stained orange but, in contrast to necrotic cells, the late apoptotic cells showed condensed and often fragmented nuclei. Necrotic cells stained orange, but had a nuclear morphology resembling that of viable cells, with no condensed chromatin. Jurkat cells treated for 4 or 24h with human activating anti-Fas antibody (CH11 clone) were used as a positive control to calculate the percentage of apoptotic cells.
For Flow Cytometry analyses the cells were treated with FcR blocking reagent (Miltenyi Biotec) and incubated with each fluorochrome- conjugated antibody or appropriate isotype control at 4°C for 30 min in the dark. Cells were then fixed for 15 minutes at 4° C with 2% PFA and washed with staining buffer (PBS, calcium and magnesium free, supplemented with 1% bovine serum albumin (BSA, SigmaAldrich) ) . T-cell phenotype was determined by using CD25 (IL-2 Receptor ) PerCPCy™5.5, FoxP3 (Scurfin, IPEX, JM2) PE, CD4 FITC, CD69 PE (Very Early Activation Antigen) , CD8 FITC/PE, CD3 FITC, CD152 (CTLA-4) PE, CD28 (TLR2) PE, IFN-γ PE, IL-4 PE, IL-17 PE, RORyt PE, IL-10 PE all purchased from BD Pharmingen. Intracellular staining was performed using BD Cytofix/Cytoperm™ Plus Fixation/Permeabilization Kit (with BD GolgiStop™ proteintransport inhibitor) (BD Pharmingen) , according to the manufacturer's instructions. For cytokine detection, BD GolgiStop
protein transport inhibitor, containing raonensin, was added in the culture for 5 hours before cellular harvesting. f-LSC immunophenotype was determined using the following monoclonal antibodies: HLA-DR FITC, CD80 (B7-1) PE, CD86 (B70/B7-2) PE, PD-1 (CD279) PE, CD34 FITC, CD45 FITC, CD274 (B7-H1, PD-L1) PE, CD273 (B7-DC, PD-L2) PE, B7-H4 PE (BD Biosciences) . Freshly isolated PBMCs and a primary Bone Marrow MSCs (Lonza) were used as positive controls for hematopoietic markers and stem cell/immunosuppressive markers respectively. All data were acquired on a FACSCalibur and analyzed using CELLQuest Pro software (Becton Dickinson) and are representative of at least five independent experiments .
Total RNA was extracted and purified from PBMCs or f-LSCs using RNeasy Mini Kit (Qiagen, Milan, Italy) , including a digestion step with DNase I set. RNA quantity and quality were assessed by UV spectrophotometry. l]ig total RNA were reverse transcribed in a volume of 20μ1 with Oligo dT primers (Applied Biosystems, Darmstad, Germany) and Stratascript RT (Stratagene, Amsterdam, Netherland) , according to the manufacturer's protocol. The primer pair sequences were the following:
SEQ.ID. NO.l:
PDL1 (CD274) forward primer 5 ' TTGCTGAACGCCCCATACAA 3' SEQ.ID. NO.2:
PDL1 (CD274) reverse primer 5 ' GGAATTGGTGGTGGTGGTCT 3' SEQ.ID. NO.3: βΐ TGF forward primer 5 ' GTGGACATCAACGGGTTCACT 3' SEQ.ID. NO.4: βΐ TGF reverse primer 5 ' ATGAGAAGCAGGAAAGGCCG 3' SEQ.ID. NO.5:
FasL forward primer 5 ' GCAGCCCTTCAATTACCCAT 3', SEQ.ID. NO.6:
FasL reverse primer 5 ' CAGAGGTTGGACAGGGAAGAA 3' SEQ.ID. NO.7: AIRE forward primer 5 ' CGGGGGTATAACAGCGGC 3' SEQ.ID. NO.8:
AIRE reverse primer 5 ' CCTCAGAAGCCGGCGTAG 3' SEQ.ID. NO.9:
HLAG forward primer 5 ' CTGGTTGTCCTTGCAGCTGTAG 3 ' HLAG reverse primer 5 'CCTTTTCAATCTGAGCTCTTCTTTCT 3' SEQ.ID. NO.10:
COX2 forward primer 5 ' ATCATTCACCAGGCAAATTGC 3', SEQ.ID. NO.11:
COX2 reverse primer 5 ' GGCTTCAGCATAAAGCGTTTG 3' SEQ.ID. NO.12:
HGF forward primer 5 ' CTC ACA CCC GCT GGG AGT AC 3' SEQ.ID. NO.13:
HGF reverse primer 5 ' TCC TTG ACC TTG GAT GCA TTC 3'
The primer set for HLA-G was selected to amplify all alternative forms of HLA-G transcripts. PCR primers for IL-6, FAS, IDO, MCP1, CCND1 and p27 were purchased from Qiagen (QuantiTect Primer Assays, Qiagen) . All reactions were performed with Quantitect Sybr Green PCR Kit (Qiagen) using the Rotor-Gene Q instrument (Qiagen) . The specificity of the amplified products was determined by melting peak analysis. Relative gene expression analysis for each gene was performed by Rotor-Gene Q
software using the delta delta Ct method validated according to the guidelines of Livak and Schmittgen (2001) . Briefly, each sample was first normalized for the amount of template added by comparison with the normalizing gene (β-actin) . These normalized values were further normalized relative to a calibrator treatment (untreated control) . All reactions were performed at least in triplicate.
PBMCs from HT patients and healthy donors were labelled with CellTraceTM Carboxyfluorescein succinimidyl ester (CFSE) using Cell Proliferation Kit (Molecular Probes Invitrogen) , according to the manufacturer's instructions. Labeled PBMCs were resuspended in RPMI 1640 medium (Gibco) with 10% FBS (complete 1640 medium) , activated with 5 g/mL of anti CD3/CD28 mAbs (Sigma Aldrich) and cocultured with one-day plated f-LSCs at 100:1 ratio. After 7 days of coculture, PBMCs were gently harvested from the supernatant and CFSE fluorescence detected by flow cytometry. Samples were analyzed by Modfit LT Version 3.2 software (Verity Software House) and the proliferation index calculated as the sum of cells in all generations divided by the number of original parent cells.
The F-LSCs used in the co-culture experiments exhibited the expected fibroblast-like morphology after Acridine/Orange staining and expressed the phenotypic markers shown in Figure 1. Freshly isolated PBMCs and primary Bone Marrow MSCs (Lonza) were used as positive controls for hematopoietic and stem cell/immunosuppressive markers respectively. QRT-PCR and flow cytometry staining was performed to determine the presence of key factors involved in immunoregulation . At passage 3 over 95% of growing cells were negative for the co- stimulatory molecules CD80 (B7-1) , CD86 (B70/B7-2) , the Human Leukocyte Antigen-DR (HLA-DR) , the immune T-activator molecule PD-1 (CD279) , the hematopoietic markers CD34, CD45 and the epithelial marker Δρ63, whereas the majority of them expressed the sternness markers SSEA4, SOX2, CD105, OCT4, NANOG, CD90 and were able to differentiate into adipocytes, condrocytes and osteocytes. It was
found that f-LSCs, constitutively and at the same levels as Bone Marrow-derived MSCs (BMMSCs ) , expressed transcripts required to modulate an immune response like TGF-β, PDL-1, Aire and Fas. The weak expression of CD95 but the total absence of CD95L in f-LSCs did not suggest Fas-FasL mediated immunoregulation . In contrast, constitutive HLAG, IDO and IL-6 expression were approximately 4/5-fold lower compared to the positive control. The primer set used in this study detected for all HLAG mRNA-spliced isoforms. Interestingly, f-LSCs significantly differed from BM-MSCs for expression of HGF, COX-2 and the monocyte chemotactic protein-1 (MCP-1 or CCL2 ) found 10, 50, 90- fold higher respectively. In addition they showed an appreciably constitutive expression for, CD274 (PD-L1) and CD273 (PDL-2) and weak positivity only for the negative regulator of T cell response B7-H4 at protein level (Fig 1 and 2) . The inhibitory molecules PD-L1 and PDL-2 have been shown to negatively interfere with the immune responses. The receptor of these ligands, PD-1, is an immunoinhibitory receptor expressed by activated T cells. Engagement of PD-1 by PD-L1 and PDL-2 leads to inhibition of T-cell receptor-mediated lymphocyte activation. Taken together these findings suggested that f-LSCs exhibited the machinery required to induce immunomodulation and immunosuppression.
To explore the inflammatory effect on the immunosuppressive capability of f-LSCs we cultured them for 48h with two Thl-related cytokines (IL-Ιβ and
IL-6 at 250U/ml) miming a typical inflammatory environment provided by lymphocytes in patients with HT . During the culture f-LSCs appeared to grow moderately faster according to the MTT assay (Fig. ID) , showing regular morphology when compared to the untreated negative control (Fig. 3) . Next we assessed their immunophenotyping by qRT-PCR and flow cytometry after cytokine treatment. Our results showed maintenance at baseline of mRNA for HLA-G, TGF-β, IDO and AIRE. The expression for COX-2 and HGF was preserved at sustained levels. The apoptotic marker CD95 halved in expression while CD95L was still totally absent.
Notably, mRNA for PDL-1, MCP-1 and IL-6 was found upregulated 2, 25 and 60-fold respectively. We observed an increase in PDL-1 and PDL-2 protein expression (40%±2.3 vs. 7013.5 and 66%±4.2 vs. 8612.5 respectively) , and no changes were found for the co-stimulatory molecules CD80 and CD86, the immune regulatory molecules B7H4, PD-1 and the Human Leukocyte Antigen-antigen DR (Fig. 1) . Taken together these data confirmed the capability of f-LSCs to enhance their immunosuppressive phenotype increasing the key immunomodulator markers PDL-1, PDL-2, IL-6 and MCP1 in an inflammatory environment (Fig. 2) . Furthermore, this trend did not affect the expression of the co- stimulatory markers CD80, CD86, the immune regulatory molecule PD-1 and the MHC class II cell surface receptor.
F-LSCs from healthy voluntaries were cocultured with anti-CD3/28 stimulated PBMCs from at 1:100 ratio for 72h. Using phase-contrast microscopy we observed that activated lymphocytes formed numbers of cell clumps of different size in the absence of f-LSCs. However, the number of cell clumps was significantly reduced after f-LSC coculture and the majority of lymphocytes were individually distributed in the medium or closely adherent to the f-LSCs. Comparable results were also obtained in mixed leukocyte reactions .
To explore the cell cycle, DNA content was measured in PBMCs from healthy donors using Propidium Iodide staining. Analysis of the cell cycle showed that the 24% ±2.3 of PBMCs after 72 hours of activation were in the G2/S phase. In the presence of f-LSCs, most cells (85%±1.2) remained in the G0/G1 phase, like the unstimulated control cells (94%±2.8) (Fig. 4) . A previous study on T-cell cycle entry defined a commitment point at early Gl where cells decide whether to enter the cell cycle and it is associated with induction of cyclin Dl expression [Lea NC, Orr SJ, Stoeber K, et al . Committment point during GO 3 Gl that controls entry into the cell cycle, Mol Cell Biol. 2003;23:2351-2361]. To confirm the cell cycle results by FACS, quantitative molecular assay was performed for cyclin Dl, and the
inhibitor p27Kipl. For this purpose, PBMCs from healthy volunteers were stimulated with anti-CD3/28 in the presence or absence of f-LSCs . After 72h hours, activated PBMCs were investigated by qRT-PCR for expression of cyclin Dl and p27Kipl as Gl phase-specific markers. Unstimulated PBMCs with or without f-LSCs exhibited constitutive levels of cyclin Dl and a high expression level of the negative cell cycle regulatory protein p27Kipl. In response to anti- CD3/C28, cyclin Dl did not change in expression whereas p27Kipl was significantly downregulated to induce cell cycle entry. Notably, the expression of p27Kipl was induced in stimulated PBMCs that had been cocultured with f-LSCs, suggesting the possibility that f-LSCs exert their growth inhibitory effect primarily through induction of p27Kipl expression.
To evaluate immune regulation of f-LSCs on T subsets, f-LSCs were cocultured 72h with PBMCs from healthy volunteers in the presence of anti-CD3/28 mAbs and analyzed by flow cytometry for some conventional activation markers (CD28, PD-1, CD69) and for CD4 and CD8 T-surface markers. After coculture with f-LSCs we found a consistent down- regulation of the two activation markers CD28 and PD-1 in PBMCs collected from young volunteers (66%±1.3 vs. 38% ±3.2 and 17%±1.0 vs. 5%±1.6 respectively) . Higher levels of CD69 (21%±1.9 vs. 39%±2.1) were detected under the same conditions (Fig. 5) . The activation marker CD69 is a target of canonical nuclear factor kappa-B (NF-kB) signaling and is transiently expressed upon activation; however, stable CD69 expression defines cells with immunoregulatory properties. In an immunoregulatory context, late and sustained CD69 expression is promoted by the non-canonical pathway and is inhibited by canonical NF-kB signaling [Felipe Saldanha Araujo, Rodrigo Haddad, Kelen C. R. Malmegrim de Farias, Alessandra de Paula Alves Souza, Patricia V. Palma, Amelia G. Araujo, Maristela D. Orellana, Julio C. Voltarelli, Dimas T. Covas, Marco A. Zago, Rodrigo A. Panepucci . Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and non-canonical NF-kB signaling. J. Cell. Mol. Med. Vol 16, No 6, 2012 pp. 1232-1244] . Furthermore, after
f-LSC stimulation, the percentages of total CD4 s increased (19%±0.8 vs. 27%±0.2) whereas the CD8+ fraction level was similar to the control (13%±0.1 vs. 11%±0.2) . Ultimately, the CD4/CD8 ratio was appreciably upregulated (Fig. 6) . We also investigated whether the inhibitory and tolerogenic effects of f-LSCs involved Treg cells, which are CD4+CD25highFoxp3+ [Sakaguchi S, Sakaguchi N, Shimizu J et al . Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18 -32]. We performed flow cytometric analysis for CD4+CD25high cells from PBMCs of healthy controls after 3 days of incubation with f-LSCs in the presence of anti-CD3/28 mAbs. There was a faint reduction in the CD4+CD25high fraction of stimulated PBMCs, as shown in figure 7. This could be the consequence of a lower activation state induced by f-LSCs on PBMCs. Notably, inside the gated CD4+CD25hl9h portion the preservation of CD4+Foxp3+ cells was found when f-LSCs were added to the culture. Taken together these results indicated that f-LSCs displayed immune regulation on both CD4+ and CD8+ T cell subsets.
Next, using CFSE we compared the proliferation state of responding PBMCs from healthy controls and HT patients stimulated with anti-CD3 and anti-CD28 mAbs with or without f-LSCs for 72h. Unstimulated PBMCs without f-LSCs were used as a negative control. The proliferation index, useful for determining the antiproliferative effects of f-LSCs on activated lymphocytes, was calculated as the sum of cells in all generations divided by the number of original parent cells. The CFSE results, shown in Figure 8, indicated that PBMCs from healthy volunteers and HT patients, grown in culture without mitogen antibodies, after a 7 day-period of incubation yielded proliferation indexes of 1.4410.03 and 1.4310.1 respectively (negative control) . Stimulation with anti-CD3/28 mAbs significantly increased the proliferation of lymphocytes (proliferation index, 2.510.5 in healthy controls vs. 3.8410.3 in patients) . The coculture of anti-CD3/28 stimulated PBMCs with f-LSCs (100:1 ratio) produced a proliferation
index of 1.75±0.1 in volunteers vs. 2.2710.5 in HT patients, representing a significant impairment, slightly superior in lymphocytes from patients respect controls, of activated PBMCs .
Several studies have suggested that MSCs modulate the differentiation, function, and balance of the thl,th2,thl7 subpopulations and foster the development of an anti-inflammatory immune response [S. Aggar al and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses," Blood, vol. 105, no. 4, pp. 1815-1822, 2005]. To study the Th balance induced by f-LSCs in activated-PBMCs some typical pro- and anti-inflammatory cytokines and the transcription factors for IL-17A, ROR-γΤ, were investigated by intracellular flow staining. The intracellular production of IFN-γ, IL-17A and ROR-γΤ was considerably decreased in cocultured cells from HT patients compared to only activated cells without f-LSCs (18%±2.1 vs. 9%±0.9; 69%±6.5 vs. 3813.4; 27%±1.5 vs. 14%±0.6 respectively) . By contrast, f-LSCs did not inhibit, at the same levels, the expression of the aforementioned cytokines on PBMCs from healthy controls (9%±1.0 vs. 4%±0.9; 8%±1.2 vs. 710.4; 20%±1.5 vs. 15%±1.6 respectively) . Notably, IL-4 secretion by Th2 was induced in the presence of f-LSCs specially in lymphocytes from HT patients (15%±2.1 vs. 28%±0.9) compared to healthy donors (20%±0.6 vs. 25%±0.5) (Fig. 9) . Overall, these data suggested that the activation of naive T cells toward a Thl or Thl7 immunophenotype was suppressed by f-LSCs through downmodulation of proinflammatory cytokines and induction of Th2 cytokines, especially in lymphocytes from HT patients. This action could be due to a superior inflammatory background level present in PBMCs from HT patients compared to healthy controls .
As described above f-LSCs inhibit lymphocyte proliferation and modulate cytokine production. They are also immunologically privileged as they do not express the complete pattern of molecules required to fully activate T-lymphocytes . In particular they are negative for the major histocompatibility (MHC) class II, co-stimulatory (CD80 or CD86)
molecules, the hematopoietic markers CD34, CD45 and the epithelial marker Δρ63 even if an inflammatory background is present. Their immunomodulatory effects also depend on both cell contact and soluble factors produced. Among them we detected the following: TGF-β, PDL- 1/2, HLAG, IDO, IL-6, HGF, COX-2 and MCP-1 (CCL2) . Human f-LSCs differ from Bone Marrow-derived MSCs for the more elevated expression of HGF, COX-2 and MCP-1. As a consequence of their sensitivity to an inflammatory environment, human f-LSCs adjust their phenotype and their expression for immunoregulatory mediators after exposure to IL- 1β and IL-6. Our results after 48h of cytokine treatment show the following: maintenance at baseline of mRNA for HLA-G, TGF-β, IDO and AIRE; preservation at sustained levels of mRNA for COX-2 and HGF; upregulation of mRNA for MCP-1 and IL-6; absence and halving of mRNA for CD95L and CD95 respectively; an increase in PDL-1 and PDL-2 expression at protein level. No impact on HLA-DR expression and the co-stimulatory molecules, both critical for immune response activation, induced by cytokines is observed. The upregulation of PDL-1 and PDL-2 in f-LSCs could optimize the induced immunosuppression and the cytokine balance in HT patients. The high expression of COX-2 enzyme, as a source of PGE2, could favour Th2-like cytokine secretion by inhibiting both Thl and Thl7 associated proliferation, and at the same time by enhancing production of IL-4. Upregulation of the chemotactic molecule MCP-1 could help attraction of T cells into close proximity of f-LSCs, where high concentrations of cytotoxic factors synergically may act to suppress immunoinflammation . Cocultured f- LSCs with allogenic PBMCs from healthy donors and HT patients in the presence of anti-CD3/28 mitogen antibodies (1:100 ratio) fail to induce a full allogeneic T-lymphocyte response suppressing up to 40% of PBMC proliferation in HT patients. At the molecular level this is mediated by upregulation of Cyclindependent kinase inhibitor IB (p27Kipl) inducing a T cell anergy status. The CD4/CD8 ratio is significantly inverted in PBMCs from healthy donors after coculture with f-LSCs proving a negative regulation action of f-LSCs on CD8+ T
cells. The CD69 expression is significantly upregulated on activated PBMCs when coculture with f-LSCs becoming immunomodulatory cells. Flow cytometry analyses indicate a faint reduction in CD25 expression and preservation of CD4+FoxP3+ cells in the presence or absence of f-LSCs, suggesting that the suppressive effect of f-LSCs is not mediated through induction of regulatory T cells. Therefore f-LSCs seem to influence the Th subset balance by altering the cytokine profile of T lymphocytes. By decreasing the T lymphocyte expression of IFN-γ, IL- 17A and RORyT human f-LSCs attenuate the differentiation of naive CD4+ T cells into Thl and Thl7 effectors. In parallel, the IL-4 expression is improved by shifting the total balance from Thl-driven responses to a more anti-inflammatory Th2 profile. Down-regulation of ROR-γ, the key transcription factor of IL-17A, at protein level suggests the capability of f-LSCs to also modulate Thl7 differentiation in favour of IL-4- producing Th2 cells. This phenomenon is more evident in PBMCs coculture with f-LSCs isolated from HT patients. This effect may depend on an inflammatory background able to stimulate or maintain the immune process in AITD patients.
Claims
1. In vitro method to restore immuno-tolerance in autoreactive peripheral blood mononuclear cells (PBMC) by co-culturing with limbal stem cells (f-LSC) in a ratio of 100:1.
2. Method according to claim 1 wherein the peripheral blood mononuclear cells (PBMC) are human-derived cells from subjects with organ-specific autoimmune diseases and/or endocrine autoimmune diseases .
3. Method according to claim 1 wherein the limbal stem cells (f-LSC) are heterologous and/or autologous.
4. Method according to claim 1 wherein co-culturing is carried out in a cell culture medium without glutamine, HEPES and Phenol red, supplemented with glutamine in a concentration between 2 and 4mM, and Fetal Bovine Serum FBS in a concentration between 10 and 12%.
5. Method according to claim 4 wherein the cell culture medium is selected from the group consisting of RPMI-1640 Medium, RPMI-1640 Medium Dutch Modification, RPMI-1640 Medium HEPES Modification, RPMI- 1640 Medium Modified e RPMI-1640 Medium Auto-Mod for Autoclaving.
6. Method according to claim 4 wherein the cell culture medium is supplemented with antibiotics.
7. Method according to claim 6 wherein the antibiotics are streptomycin and/or penicillin.
8. Method according to claim 7 wherein the antibiotics are in a concentration of penicillin in a range between 1000 and 50000U/ml and streptomycin in a range between 50 and 500 mg/ml and more preferably 10000 U/ml of penicillin and 100 mg/ml of streptomycin.
9. Method according to claim 1 wherein the co-culturing is carried out in flasks with tissue culture-treated surfaces improving surface charge of culture vessels.
10. Method according to claim 9 wherein the flasks are culture flasks with hydrophilic surface.
11. Method according to claim 10 wherein the culture flasks are made of polystyrene functionalized with oxygen-containing functional groups .
12. Method according to claim 11 wherein the culture flasks are commercial and pretreated for enhanceing cell attachment.
13. Method according to claim 1 wherein the method comprises before co-culturing a step wherein bioptic samples from limbus are plated and growth to form adhering cell-colonies of f-LSC in HEPES containing culture medium with sodium bicarbonate pyridoxine without L-glutamine and supplemented with fetal bovine serum, IX insulin-transferrin- selenium and fibroblast growth factor.
14. Method according to claim 13 wherein the culture medium of fLSC is F12/DMEM.
15. Method according to claim 1 or 13 wherein the method comprises before co-culturing a step wherein PBMC are obtained from peripheral blood samples by separation by density gradient centrifugation from blood samples from subjects with organ-specific autoimmune diseases.
16. Method according to claim 15 wherein centrifugation is FicollPaque Density Gradient Centrifugation.
17. Peripheral blood mononuclear cells (PBMC) characterazed by immune- modulatory capability obtainable by the method according to each of preceding claims .
18. Peripheral blood mononuclear cells (PBMC) immune-educated to self obtained by the method comprising co-culturing autoreactive peripheral blood mononuclear cell (PBMC) with limbal stem cells (fLSC), in a ratio of 100:1.
19. Peripheral blood mononuclear cells (PBMC) immune-educated to self
for use in the treatment of organ-specific autoimmune diseases an endocrine autoimmune diseases.
20. Peripheral blood mononuclear cells (PBMC) immune-educated to sel for use acoording to claim 19 wherein organ-specific autoimmun diseases are Autoimmune thyroid disease (AITD) like Hashimoto' thyroiditis (HT) and Graves' disease (GD) .
21. Peripheral blood mononuclear cells (PBMC) immune-educated to sel for use according to claim 19 wherein endocrine autoimmune diseases i APS .
22. Kit of parts comprising peripheral blood mononuclear cells (PBMC from subjects with organ-specific autoimmune diseases and/or endocriri' autoimmune diseases, heterologous and/or autologous limbal stem cell (f-LSC) and all the part to carry out the co-culturing method o claims 4-16.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102016000130565A IT201600130565A1 (en) | 2016-12-23 | 2016-12-23 | In vitro cell co-culture method to induce immunological tolerance |
IT102016000130565 | 2016-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018114469A1 true WO2018114469A1 (en) | 2018-06-28 |
Family
ID=58701705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/082380 WO2018114469A1 (en) | 2016-12-23 | 2017-12-12 | In vitro cellular co-culture method to induce immunological tolerance |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT201600130565A1 (en) |
WO (1) | WO2018114469A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114736852A (en) * | 2022-06-13 | 2022-07-12 | 南京艾尔普再生医学科技有限公司 | In-vitro experimental model for myocardial cell transplantation immune rejection |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116445285A (en) * | 2023-03-28 | 2023-07-18 | 创芯国际生物科技(广州)有限公司 | Organ-like co-culture chip, construction method and co-culture method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITFI20090275A1 (en) | 2009-12-29 | 2011-06-30 | Univ Palermo | GENERATION OF PANCREATIC ENDOCRINE CELLS FROM SIMILAR-FIBROBLASTIC HUMAN LIMBARY STEM CELLS. |
WO2011087637A1 (en) * | 2009-12-08 | 2011-07-21 | The Board Of Trustees Of The University Of Illinois | Stem cell immune modulation methods of use and apparatus |
-
2016
- 2016-12-23 IT IT102016000130565A patent/IT201600130565A1/en unknown
-
2017
- 2017-12-12 WO PCT/EP2017/082380 patent/WO2018114469A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011087637A1 (en) * | 2009-12-08 | 2011-07-21 | The Board Of Trustees Of The University Of Illinois | Stem cell immune modulation methods of use and apparatus |
ITFI20090275A1 (en) | 2009-12-29 | 2011-06-30 | Univ Palermo | GENERATION OF PANCREATIC ENDOCRINE CELLS FROM SIMILAR-FIBROBLASTIC HUMAN LIMBARY STEM CELLS. |
Non-Patent Citations (31)
Title |
---|
ANTONINA COPPOLA ET AL: "Human limbal fibroblast-like stem cells induce immune-tolerance in autoreactive T lymphocytes from female patients with Hashimoto's thyroiditis", STEM CELL RESEARCH & THERAPY, vol. 8, no. 1, 3 July 2017 (2017-07-03), XP055389480, DOI: 10.1186/s13287-017-0611-5 * |
AZAR DT.: "Trans Am Ophthalmol Soc", vol. 104, 2006, AMERICAN OPHTHALMOLOGICAL SOCIETY THESIS, article "Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing", pages: 264 - 302 |
BIEBACK K; KERN S; KLUTER H; EICHLER H.: "Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood", STEM CELLS, vol. 22, no. 4, 2004, pages 625 - 34 |
CHEN, Z.; DE PAIVA, C. S.; LUO, L.; KRETZER, F. L.; PFLUGFELDER S. C.; LI, D. Q.: "Characterization of putative stem cell phenotype in human limbal epithelia", STEM CELLS, vol. 22, 2004, pages 355 - 366, XP003007062 |
CRISCIMANNA A; ZITO G; TADDEO A; RICHIUSA P; PITRONE M; MORREALE D; LODATO G; PIZZOLANTI G; CITARRELLA R; GALLUZZO A: "In vitro generation of pancreatic endocrine cells from human adult fibroblast-like limbal stem cells", CELL TRANSPLANT., vol. 21, no. 1, 2012, pages 73 - 90 |
DAVANGER, M.; EVENSEN, A.: "Role of the pericorneal papil- lary structure in renewal of corneal epithelium", NATURE, vol. 229, no. 5286, 1971, pages 560 - 1 |
DRAVIDA, S.; PAL, R.; KHANNA, A.; TIPNIS, S. P.; RAVINDRAN, G.; KHAN, F.: "The transdifferentiation potential of limbal fibroblast-like cells", DEV. BRAIN RES., vol. 160, 2005, pages 239 - 251, XP005187652, DOI: doi:10.1016/j.devbrainres.2005.09.008 |
EFFRAIMIDIS G; STRIEDER TG; TIJSSEN JG; WIERSINGA WM: "Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study", EUR J ENDOCRINOL., vol. 164, no. 1, January 2011 (2011-01-01), pages 107 - 13 |
FELIPE SALDANHA ARAUJO; RODRIGO HADDAD; KELEN C. R. MALMEGRIM DE FARIAS; ALESSANDRA DE PAULA ALVES SOUZA; PATRICIA V. PALMA; AMELI: "Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and non-canonical NF-kB signaling", J. CELL. MOL. MED., vol. 16, no. 6, 2012, pages 1232 - 1244 |
GIORDANO C; STASSI G; DE MARIA R; TODARO M; RICHIUSA P; PAPOFF G; RUBERTI G; BAGNASCO M; TESTI R; GALLUZZO A, SCIENCE, vol. 275, no. 5302, 14 February 1997 (1997-02-14), pages 960 - 3 |
HEO JS1; CHOI YL; KIM HS2; KIM HOI: "Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue", INT J MOL MED., vol. 37, no. 1, January 2016 (2016-01-01), pages 115 - 25 |
KIDD P.: "Thl/Th2 balance: The hypothesis, its limitations, and implications for health and disease", ALTERN MED REV, vol. 8, 2003, pages 223 - 246 |
KRISTENSEN B.: "Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls", DAN MED J., vol. 63, no. 2, February 2016 (2016-02-01), pages B517 |
LEA NC; ORR SJ; STOEBER K ET AL.: "Committment point during G0 3 G1 that controls entry into the cell cycle", MOL CELL BIOL., vol. 23, 2003, pages 2351 - 2361 |
LI Y; YAN B; WANG H; LI H; LI Q; ZHAO D; CHEN Y; ZHANG Y; LI W; ZHANG J: "Hair regrowth in alopecia areata patients following Stem Cell Educator therapy", BMC MED., vol. 13, 20 April 2015 (2015-04-20), pages 87, XP021221299, DOI: doi:10.1186/s12916-015-0331-6 |
M. KRAMPERA; L. COSMI; R. ANGELI ET AL.: "Role for interferon in the immunomodulatory activity of human bone marrow mesenchymal stem cells", STEM CELLS, vol. 24, no. 2, 2006, pages 386 - 398, XP002422937 |
MANLEY, N. R.: "Thymus organogenesis and molecular mechanisms of thymic epithelial cell differentiation", SEMIN. IMMUNOL., vol. 12, 2000, pages 421 - 428 |
MEISEL, A. ZIBERT; M. LARYEA; U. G''OBEL; W. D''AUBENER; D. DILLOO: "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3- dioxygenasemediated tryptophan degradation", BLOOD, vol. 103, no. 12, 2004, pages 4619 - 4621, XP002437352, DOI: doi:10.1182/blood-2003-11-3909 |
NARESH POLISETTY ET AL: "Mesenchymal cells from limbal stroma of human eye", MOLECULAR VISION, 1 January 2008 (2008-01-01), United States, pages 431, XP055389936, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268845/pdf/mv-v14-431.pdf> * |
RODEWALD, H. R.; PAUL, S.; HALLER, C.; BLUTHMANN, H.; BLUM, C.: "Thymus medullaconsisting of epithelial islets each derived from a single progenitor", NATURE, vol. 414, 2001, pages 763 - 768 |
S. AGGARWAL; M. F. PITTENGER: "Human mesenchymal stem cells modulate allogeneic immune cell responses", BLOOD, vol. 105, no. 4, 2005, pages 1815 - 1822 |
SAKAGUCHI S; SAKAGUCHI N; SHIMIZU J ET AL.: "Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance", IMMUNOL REV, vol. 182, 2001, pages 18 - 32 |
SPITS H.: "Development of alphabeta T cells in the human thymus", NAT REV IMMUNOL, vol. 2, 2002, pages 760 - 72 |
TOMASELLO L; MUSSO R; CILLINO G; PITRONE M; PIZZOLANTI G; COPPOLA A; ARANCIO W; DI CARA G; PUCCI-MINAFRA I; CILLINO S: "Donor age and long-term culture do not negatively influence the stem potential of limbal fibroblast-like stem cells", STEM CELL RES THER., vol. 7, no. 1, 13 June 2016 (2016-06-13), pages 83 |
VLADIMIR HOLAN ET AL: "Immunoregulatory Properties of Mouse Limbal Stem Cells", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 4, 11 January 2010 (2010-01-11), US, pages 2124 - 2129, XP055390116, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0903049 * |
VON BOEHMER H; FEHLING HJ: "Structure and function of the pre-T cell receptor", ANNU REV IMMUNOL, vol. 15, 1997, pages 433 - 52, XP055079326, DOI: doi:10.1146/annurev.immunol.15.1.433 |
YONATHAN GARFIAS ET AL: "Stem cells isolated from the human stromal limbus possess immunosuppressant properties", MOLECULAR VISION, 1 January 2012 (2012-01-01), United States, pages 2087, XP055389521, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413432/pdf/mv-v18-2087.pdf> * |
YONG ZHAO ET AL: "Reversal of type 1 diabetes via islet [beta] cell regeneration following immune modulation by cord blood-derived multipotent stem cells", BMC MEDICINE, BIOMED CENTRAL LTD., LONDON, GB, vol. 10, no. 1, 10 January 2012 (2012-01-10), pages 3, XP021118823, ISSN: 1741-7015, DOI: 10.1186/1741-7015-10-3 * |
ZHAO Y; JIANG Z; ZHAO T; YE M; HU C; YIN Z; LI H; ZHANG Y; DIAO Y; LI Y: "Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells", BMC MED, vol. 10, 10 January 2012 (2012-01-10), pages 3, XP021118823, DOI: doi:10.1186/1741-7015-10-3 |
ZHAO Y; JIANG Z; ZHAO T; YE M; HU C; ZHOU H; YIN Z; CHEN Y; ZHANG Y; WANG S: "Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CBSCs) in stem cell educator therapy: phase I/II clinical trial", BMC MED., vol. 11, no. 160, 9 July 2013 (2013-07-09), pages 10 |
ZOLTÁN VERÉB ET AL: "Role of Human Corneal Stroma-Derived Mesenchymal-Like Stem Cells in Corneal Immunity and Wound Healing", SCIENTIFIC REPORTS, vol. 6, no. 1, 19 May 2016 (2016-05-19), XP055389511, DOI: 10.1038/srep26227 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114736852A (en) * | 2022-06-13 | 2022-07-12 | 南京艾尔普再生医学科技有限公司 | In-vitro experimental model for myocardial cell transplantation immune rejection |
Also Published As
Publication number | Publication date |
---|---|
IT201600130565A1 (en) | 2018-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | Immunomodulatory effects of human amniotic membrane-derived mesenchymal stem cells | |
Banas et al. | Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells | |
DelaRosa et al. | Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis | |
Bassi et al. | Immune regulatory properties of multipotent mesenchymal stromal cells: where do we stand? | |
Lee et al. | Mesenchymal stem/stromal cells protect against autoimmunity via CCL2-dependent recruitment of myeloid-derived suppressor cells | |
Menard et al. | Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls | |
Gu et al. | Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells | |
Kim et al. | Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance | |
Flemming et al. | Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate | |
Najar et al. | Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation | |
KR20130128438A (en) | Treatment of immune-related diseases and disorders using amnion derived adherent cells | |
US20120121611A1 (en) | Method of treating autoimmune disease with mesenchymal stem cells | |
EP2861719B1 (en) | Compositions and methods for diminishing an immune response | |
Morse et al. | NK cell-mediated lysis of autologous human oligodendrocytes | |
Mennan et al. | Mesenchymal stromal cells derived from whole human umbilical cord exhibit similar properties to those derived from Wharton's jelly and bone marrow | |
US20110045071A1 (en) | Generation of a novel type of anti-inflammatory macrophages for clinical use | |
JP7398959B2 (en) | Mesenchymal progenitor or stem cells with improved immunosuppressive properties | |
Nazarov et al. | Assessment of immunosuppressive activity of human mesenchymal stem cells using murine antigen specific CD4 and CD8 T cells in vitro | |
Coppola et al. | Human limbal fibroblast-like stem cells induce immune-tolerance in autoreactive T lymphocytes from female patients with Hashimoto’s thyroiditis | |
US20140154227A1 (en) | Cell populations having immunoregulatory activity, method for isolation and uses | |
WO2018114469A1 (en) | In vitro cellular co-culture method to induce immunological tolerance | |
Chen et al. | The biological characteristics of sheep umbilical cord mesenchymal stem cells | |
Burt et al. | Circulating HLA-DR+ natural killer cells have potent lytic ability and weak antigen-presenting cell function | |
Thakkar et al. | Stem cell therapy: An emerging modality in glomerular diseases | |
Ghanavatinejad et al. | MenSCs exert a supportive role in establishing a pregnancy-friendly microenvironment by inhibiting TH17 polarization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17832212 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17832212 Country of ref document: EP Kind code of ref document: A1 |